Small interfering RNA against the apurinic or apyrimidinic endonuclease enhances the sensitivity of human pancreatic cancer cells to gemcitabine in vitro

Journal of Digestive Diseases

Volumn 11, Issue 4, 2010, Pages 224-230

  Xiong, Guang Su ^a   Sun, Hui Ling ^a   Wu, Shu Ming ^a   Mo, Jian Zhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

APE1 Ref 1; Gemcitabine; Pancreatic cancer; SiRNA.

Indexed keywords

DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; GEMCITABINE; MESSENGER RNA; REDOX EFFECTOR FACTOR 1; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIMETABOLITE; APEX1 PROTEIN, HUMAN; DEOXYCYTIDINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ENZYMOLOGY; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DOWN-REGULATION; HUMANS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 77955018749     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2010.00442.x     Document Type: Article

References (33)

1. Li J, Saif MW. Advancements in the management of pancreatic cancer. JOP 2009, 10:109-17.
2. Réjiba S, Bigand C, Parmentier C, Hajri A. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK:UMK GDEPT and TS/RR siRNA strategies. Neoplasia 2009, 11:637-50.
3. Jacob DA, Bahra M, Langrehr JM. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol 2007, 22:738-48.
4. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87:161-7.
5. Burris HA, Moore MJ, Andersen J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-13.
6. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997, 33(1):S18-22. Suppl.
7. Wang D, Xiang DB, Yang XQ. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66:298-304.
8. Belzile JP, Choudhury SA, Cournoyer D, Chow TY. Targeting DNA repair proteins: a promising avenue for cancer gene therapy. Curr Gene Ther 2006, 6:111-23.
9. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008, 18:80-6.
10. Adhikari S, Choudhury S, Mitra PS, Dubash JJ, Sajankila SP, Roy R. Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem 2008, 8:351-7.
11. Bapat A, Fishel ML, Kelley MR. Going ape as an approach to cancer therapeutics. Antioxid Redox Signal 2009, 11:651-68.
12. Fishel ML, He Y, Reed AM. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst) 2008, 7:177-86.
13. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004, 3:679-86.
14. Moore DH, Michael H, Tritt R, Parsons SH, Kelley MR. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin Cancer Res 2000, 6:602-9.
15. Raffoul JJ, Banerjee S, Singh-Gupta V. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007, 67:2141-9.
16. Bobola MS, Finn LS, Ellenbogen RG. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin Cancer Res 2005, 11:7405-14.
17. Lau JP, Weatherdon KL, Skalski V, Hedley DW. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer 2004, 91:1166-73.
18. Xiong GS, Wu SM, Xu XJ. Expression of APE/Ref-1 in human pancreatic cancer cell line Patu-8988 induced by gemcitabine. World Chin J Digestol 2007, 15:1425-8.
19. Xiang DB, Chen ZT, Wang D. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther 2008, 15:625-35.
20. Bobola MS, Emond MJ, Blank A. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin Cancer Res 2004, 10:7875-83.
21. Kelley MR, Cheng L, Foster R. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/Ref-1 in prostate cancer. Clin Cancer Res 2001, 7:824-30.
22. Robertson KA, Bullock HA, Xu Y. Altered expression of Ape1/Ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res 2001, 61:2220-5.
23. Silber JR, Bobola MS, Blank A. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 2002, 8:3008-18.
24. Yang ZZ, Li MX, Zhang YS. Knock down of the dual functional protein apurinic/apyrimidinic endonuclease 1 enhances the killing effect of hematoporphrphyrin derivative-mediated photodynamic therapy on non-small cell lung cancer cells in vitro and in a xenograft model. Cancer Sci 2009, 101:180-7.
25. Luo M, Delaplane S, Jiang A. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid Redox Signal 2008, 10:1853-67.
26. Fishel ML, Kelley MR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 2007, 28:375-95.
27. Chang Q, Qin R, Huang T, Gao J, Feng Y. Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas 2006, 32:297-305.
28. Yang L, Kang WK. The effect of HIF-1alpha siRNA on growth and chemosensitivity of MIA-paca cell line. Yonsei Med J 2008, 49:295-300.
29. Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res 2009, 29:3173-8.
30. Lo YL, Jou YS, Hsiao CF. A polymorphism in the APE1 gene promoter is associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2009, 18:223-9.
31. Jiao L, Bondy ML, Hassan MM. Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev 2006, 30:284-91.
32. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 2005, 7:395-403.
33. Zou GM, Maitra A. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther 2008, 7:2012-21.